Publications by authors named "David B Clemow"

Claim this Profile
T
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Bruce E Sands, Geert D'Haens, David B Clemow, Peter M Irving, Jordan T Johns

Inflamm Bowel Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumab.
David B Clemow, Marla C Dubinsky, Simin K Baygani, Bruce E Sands, Anthony Keohane

J Patient Rep Outcomes· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Bruce E Sands, Geert D'Haens, David B Clemow, Peter M Irving, Jordan T Johns

Inflamm Bowel Dis· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission.
Marla C Dubinsky, David B Clemow, Theresa Hunter Gibble, Xingyuan Li, Severine Vermeire

Crohns Colitis 360· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine.
David B Clemow, Helen M Hochstetler, Yan Dong, Paula Hauck, Mario F P Peres

Postgrad Med· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lasmiditan in patients with common migraine comorbidities: a efficacy and safety analysis of two phase 3 randomized clinical trials.
David B Clemow, Simin K Baygani, Paula M Hauck, Cory B Hultman

Curr Med Res Opin· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lasmiditan mechanism of action - review of a selective 5-HT agonist.
David B Clemow, Kirk W Johnson, Helen M Hochstetler, Michael H Ossipov, Ann M Hake

J Headache Pain· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study.
David B Clemow, Oren W Mason, Elias H Sarkis, Dustin D Ruff, Brad D Berman

Expert Rev Neurother· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medical Writing Competency Model - Section 1: Functions, Tasks, and Activities.
David B Clemow, Bertil Wagner, Christopher Marshallsay, Dan Benau, Darryl L'Heureux

Ther Innov Regul Sci· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medical Writing Competency Model - Section 2: Knowledge, Skills, Abilities, and Behaviors.
David B Clemow, Bertil Wagner, Christopher Marshallsay, Dan Benau, Darryl L'Heureux

Ther Innov Regul Sci· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Misuse of Methylphenidate.
David B Clemow

Curr Top Behav Neurosci· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities.
David B Clemow, Chris Bushe, Michele Mancini, Michael H Ossipov, Himanshu Upadhyaya

Neuropsychiatr Dis Treat· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention-Deficit/Hyperactivity Disorder.
David B Clemow, Allen W Nyhuis, Rebecca L Robinson

CNS Neurosci Ther· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials.
Linda A Wietecha, David B Clemow, Andrew S Buchanan, Joel L Young, Elias H Sarkis

CNS Neurosci Ther· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Dosing Patterns of Atomoxetine in Adults with Attention-Deficit/Hyperactivity Disorder.
Samaneh Kabul, Carlos Alatorre, Leslie B Montejano, Amanda M Farr, David B Clemow

CNS Neurosci Ther· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients.
David B Clemow, Chris J Bushe

J Psychopharmacol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder.
Daniel J Walker, Oren Mason, David B Clemow, Kathleen A Day

Postgrad Med· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atomoxetine effects on executive function as measured by the BRIEF--a in young adults with ADHD: a randomized, double-blind, placebo-controlled study.
Lenard A Adler, David B Clemow, David W Williams, Todd M Durell

PLoS One· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medicines in Pregnancy Forum: Proceedings on Ethical and Legal Considerations.
David B Clemow, Martha R Nolan, Debra L Michaels, Andreas M Kogelnik, Susan A Cantrell

Ther Innov Regul Sci· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duloxetine Compared with Pregabalin for Diabetic Peripheral Neuropathic Pain Management in Patients with Suboptimal Pain Response to Gabapentin and Treated with or without Antidepressants: A Post Hoc Analysis.
Robert J Tanenberg, David B Clemow, Joseph M Giaconia, Richard C Risser

Pain Pract· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potential for misuse and abuse of medications in ADHD: a review.
David B Clemow, Daniel J Walker

Postgrad Med· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suboptimal dosing of Strattera (atomoxetine) for ADHD patients.
David B Clemow

Postgrad Med· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Proposed Framework to Address Needs of Clinical Data for Informed Medication Use in Pregnancy.
David B Clemow, Lode Dewulf, Debra L Michaels, Martha R Nolan, Susan A Cantrell

Ther Innov Regul Sci· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Data for Informed Medication Use in Pregnancy: Strengths, Limitations, Gaps, and a Need to Continue Moving Forward.
David B Clemow, Lode Dewulf, Gideon Koren, J Stephen Mikita, Martha R Nolan

Ther Innov Regul Sci· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.
Scott W Andersen, David B Clemow, Sara A Corya

J Clin Psychiatry· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis